Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.16 USD -0.27%
Market Cap: 4.8B USD
Have any thoughts about
Alkermes Plc?
Write Note

Intrinsic Value

The intrinsic value of one ALKS stock under the Base Case scenario is 28.4 USD. Compared to the current market price of 29.16 USD, Alkermes Plc is Overvalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALKS Intrinsic Value
28.4 USD
Overvaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Alkermes Plc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALKS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALKS?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Alkermes Plc

Provide an overview of the primary business activities
of Alkermes Plc.

What unique competitive advantages
does Alkermes Plc hold over its rivals?

What risks and challenges
does Alkermes Plc face in the near future?

Has there been any significant insider trading activity
in Alkermes Plc recently?

Summarize the latest earnings call
of Alkermes Plc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Alkermes Plc.

Provide P/S
for Alkermes Plc.

Provide P/E
for Alkermes Plc.

Provide P/OCF
for Alkermes Plc.

Provide P/FCFE
for Alkermes Plc.

Provide P/B
for Alkermes Plc.

Provide EV/S
for Alkermes Plc.

Provide EV/GP
for Alkermes Plc.

Provide EV/EBITDA
for Alkermes Plc.

Provide EV/EBIT
for Alkermes Plc.

Provide EV/OCF
for Alkermes Plc.

Provide EV/FCFF
for Alkermes Plc.

Provide EV/IC
for Alkermes Plc.

Show me price targets
for Alkermes Plc made by professional analysts.

What are the Revenue projections
for Alkermes Plc?

How accurate were the past Revenue estimates
for Alkermes Plc?

What are the Net Income projections
for Alkermes Plc?

How accurate were the past Net Income estimates
for Alkermes Plc?

What are the EPS projections
for Alkermes Plc?

How accurate were the past EPS estimates
for Alkermes Plc?

What are the EBIT projections
for Alkermes Plc?

How accurate were the past EBIT estimates
for Alkermes Plc?

Compare the revenue forecasts
for Alkermes Plc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Alkermes Plc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Alkermes Plc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Alkermes Plc compared to its peers.

Compare the P/E ratios
of Alkermes Plc against its peers.

Discuss the investment returns and shareholder value creation
comparing Alkermes Plc with its peers.

Analyze the financial leverage
of Alkermes Plc compared to its main competitors.

Show all profitability ratios
for Alkermes Plc.

Provide ROE
for Alkermes Plc.

Provide ROA
for Alkermes Plc.

Provide ROIC
for Alkermes Plc.

Provide ROCE
for Alkermes Plc.

Provide Gross Margin
for Alkermes Plc.

Provide Operating Margin
for Alkermes Plc.

Provide Net Margin
for Alkermes Plc.

Provide FCF Margin
for Alkermes Plc.

Show all solvency ratios
for Alkermes Plc.

Provide D/E Ratio
for Alkermes Plc.

Provide D/A Ratio
for Alkermes Plc.

Provide Interest Coverage Ratio
for Alkermes Plc.

Provide Altman Z-Score Ratio
for Alkermes Plc.

Provide Quick Ratio
for Alkermes Plc.

Provide Current Ratio
for Alkermes Plc.

Provide Cash Ratio
for Alkermes Plc.

What is the historical Revenue growth
over the last 5 years for Alkermes Plc?

What is the historical Net Income growth
over the last 5 years for Alkermes Plc?

What is the current Free Cash Flow
of Alkermes Plc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Alkermes Plc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alkermes Plc

Current Assets 1.6B
Cash & Short-Term Investments 908.9m
Receivables 370.2m
Other Current Assets 285.1m
Non-Current Assets 591.1m
Long-Term Investments 18.9m
PP&E 311.5m
Intangibles 83.9m
Other Non-Current Assets 176.8m
Current Liabilities 453.7m
Accounts Payable 37m
Accrued Liabilities 411.3m
Other Current Liabilities 5.3m
Non-Current Liabilities 409.5m
Long-Term Debt 285.8m
Other Non-Current Liabilities 123.7m
Efficiency

Earnings Waterfall
Alkermes Plc

Revenue
1.5B USD
Cost of Revenue
-253.3m USD
Gross Profit
1.3B USD
Operating Expenses
-815.3m USD
Operating Income
436.5m USD
Other Expenses
-103.2m USD
Net Income
333.3m USD

Free Cash Flow Analysis
Alkermes Plc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ALKS Profitability Score
Profitability Due Diligence

Alkermes Plc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

60/100
Profitability
Score

Alkermes Plc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

ALKS Solvency Score
Solvency Due Diligence

Alkermes Plc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Low D/E
Negative Net Debt
75/100
Solvency
Score

Alkermes Plc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALKS Price Targets Summary
Alkermes Plc

Wall Street analysts forecast ALKS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALKS is 35.62 USD with a low forecast of 21.21 USD and a high forecast of 52.5 USD.

Lowest
Price Target
21.21 USD
27% Downside
Average
Price Target
35.62 USD
22% Upside
Highest
Price Target
52.5 USD
80% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALKS?

Click here to dive deeper.

Dividends

Alkermes Plc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALKS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ALKS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ALKS News

Other Videos

Profile

Alkermes Plc Logo
Alkermes Plc

Country

Ireland

Industry

Biotechnology

Market Cap

4.7B USD

Dividend Yield

0%

Description

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Contact

DUBLIN
DUBLIN
Connaught HSE, 1 Burlington Road
+35317728000.0
www.alkermes.com

IPO

1991-07-16

Employees

2 211

Officers

Chairman & CEO
Mr. Richard F. Pops
Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO
Mr. Blair C. Jackson
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
Mr. David Joseph Gaffin
Senior VP & CFO
Mr. Iain Michael Brown
Executive VP of Research & Development and Chief Medical Officer
Dr. Craig C. Hopkinson M.D.
Founder
Dr. Floyd E. Bloom M.D.
Show More
Interim Principal Accounting Officer & VP of Finance
Mr. Samuel J. Parisi
Chief Information Officer & Senior VP of IT
Mr. Thomas Harvey
Senior Vice President of Corporate Affairs & Investor Relations
Ms. Sandra Coombs
Senior VP & Chief Human Resources Officer
Mr. Stephen Schiavo
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALKS stock?

The intrinsic value of one ALKS stock under the Base Case scenario is 28.4 USD.

Is ALKS stock undervalued or overvalued?

Compared to the current market price of 29.16 USD, Alkermes Plc is Overvalued by 3%.

Back to Top